MYOBLOC

DRUG3 trials

Sponsors

Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC, Georgetown University

Conditions

Brain InjurySialorrheaSpasticity Secondary to Either a Disorder or TraumaSpinal Cord Injury (SCI)StrokeTumor

Phase 3

Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects

CompletedNCT01994109

Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLCSialorrhea

Start: 2013-11-01End: 2017-01-01Updated: 2026-04-21

Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults

CompletedNCT02610868

Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLCSialorrhea

Start: 2015-10-01End: 2017-06-01Updated: 2026-04-21

Phase 4

Myobloc Atrophy Study

CompletedNCT02052024

Georgetown UniversityBrain Injury, Spasticity Secondary to Either a Disorder or Trauma, Spinal Cord Injury (SCI) +2

Start: 2014-05-31End: 2015-08-31Updated: 2015-12-16

Related Papers

Long-Term Safety and Efficacy of Repeated Cycles of RimabotulinumtoxinB in the Treatment of Chronic Sialorrhea: Results of the OPTIMYST Trial

Neurology and Therapy2025-06-10

Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults

JAMA Neurology2020-01-1362 citations